

1 **Salivary profiles of 11-oxygenated androgens follow a diurnal rhythm in patients with**
2 **congenital adrenal hyperplasia**

3

4 Hanna Nowotny^{1*}, Matthias K. Auer^{1*}, Christian Lottspeich¹, Heinrich Schmidt², Ilija Dubinski², Martin
5 Bidlingmaier¹, Jo Adaway³, James Hawley³, Brian Keevil³, Nicole Reisch¹

6 ¹Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich,
7 Germany

8 ²Department of Pediatric Endocrinology, Dr. von Haunersches Children's Hospital, Klinikum der
9 Universität München, LMU München, Munich, Germany

10 ³Department of Clinical Biochemistry, Manchester University Foundation NHS Trust, Manchester
11 Academic Health Sciences Centre, Southmoor Rd, Manchester, UK

12

13 *These authors contributed equally.

14

15 **Correspondence:**

16 Nicole Reisch

17 Medizinische Klinik and Poliklinik IV, Klinikum der Universität München

18 Ziemssenstr. 1

19 80336 München

20 Germany

21 Email: Nicole.reisch@med.uni-muenchen.de

22

23 **Short title:** Diurnal rhythm of 11-oxygenated androgens

24 **Keywords:** Congenital adrenal hyperplasia, saliva, diurnal rhythm, 11-ketotestosterone,

25 11-oxygenated androgens

26

27 **Funding:** This work was supported by the Deutsche Forschungsgemeinschaft (Heisenberg
28 Professorship 325768017 to NR and Projektnummer: 314061271-TRR205 to NR).

29

30 **Disclosure:** The authors report no conflicts of interest in this work.

31

32 **Abbreviations**

33	11 β -HSD2	11 β -hydroxysteroid dehydrogenase type 2
34	11oxC19	11-oxygenated 19-carbon
35	11OHA4	11 β -hydroxyandrostenedione
36	11KA4	11-ketoandrostenedione
37	11KDHT	11-ketodihydrotestosterone
38	11KT	11-ketotestosterone
39	11OHT	11-hydroxytestosterone
40	21DF	21-deoxycortisol
41	21OHD	21-hydroxylase deficiency
42	A4	androstenedione
43	ACTH	adrenocorticotrophic hormone
44	AUC	area under the curve
45	CAH	congenital adrenal hyperplasia
46	CRH	corticotropin releasing hormone
47	CYP11B1	11 β -hydroxylase
48	DHT	dihydrotestosterone
49	GC	glucocorticoid
50	HPA	hypothalamic-pituitary-axis
51	HPG	hypothalamic-pituitary-gonadal
52	LLOQ	lowest limits of quantification
53	LP-MS/MS	liquid chromatography-mass spectrometry
54	PVN	paraventricular nucleus
55	StAR	steroidogenic acute regulatory protein
56	SCN	suprachiasmatic nucleus
57	T	testosterone
58	TART	testicular adrenal rest tumors
59	UPC ² -MS/MS	ultra-performance convergence chromatography tandem mass
60		spectrometry

61

62

63 **Abstract**

64 **Context:**

65 Several studies have highlighted the importance of the 11-oxygenated 19-carbon (11oxC19)
66 adrenal-derived steroids as potential biomarkers for monitoring patients with 21-hydroxylase
67 deficiency (21OHD).

68

69 **Objective:**

70 To analyze circadian rhythmicity of 11oxC19 steroids in saliva profiles and evaluate their relevance as
71 potential monitoring parameters in 21OHD.

72

73 **Design, Setting, and Participants:**

74 Cross-sectional single center study including 34 patients with classic 21OHD (men=14; women=20)
75 and 32 BMI- and age-matched controls (men=15; women=17).

76

77 **Outcome Measures:**

78 Salivary concentrations of the following steroids were analyzed by LC-MS/MS:
79 17-hydroxyprogesterone (17OHP), androstenedione (A4), testosterone (T),
80 11 β -hydroxyandrostenedione (11OHA4) and 11-ketotestosterone (11KT).

81

82 **Results:** Similar to the previously described rhythmicity of 17OHP, 11OHA4 and 11KT concentrations
83 followed a distinct diurnal rhythm in both patients and controls with highest concentrations in the early
84 morning and declining throughout the day (**11-OHA4:** male patients $\Delta_{\text{mean}} = 79\%$; male controls $\Delta_{\text{mean}} = 81\%$;
85 female patients $\Delta_{\text{mean}} = 33\%$; female controls $\Delta_{\text{mean}} = 91\%$; **11KT:** male patients $\Delta_{\text{mean}} = 64\%$;
86 male controls $\Delta_{\text{mean}} = 60\%$; female patients $\Delta_{\text{mean}} = 49\%$; female controls $\Delta_{\text{mean}} = 81\%$). Significant
87 correlations between the area under the curve (AUC) for 17OHP and 11KT ($r(p)_{\text{male}} = 0.741^{**}$; $r(p)_{\text{female}}$
88 $= 0.842^{****}$), and 11OHA4 ($r(p)_{\text{male}} = 0.385^{\text{n.s.}}$; $r(p)_{\text{female}} = 0.527^*$) were observed in patients but not in
89 controls.

90

91 **Conclusions:** Adrenal 11oxC19 androgens are secreted following a diurnal pattern. This should be
92 considered when evaluating their utility for monitoring treatment control.

93 **Introduction**

94 Classic congenital adrenal hyperplasia (CAH) secondary to 21-hydroxylase deficiency (21OHD) is
95 characterized by insufficient cortisol synthesis; and, in approximately two-thirds of patients,
96 aldosterone production is also affected. Patients affected by CAH require life-long glucocorticoid (GC)
97 and, where appropriate, mineralocorticoid replacement therapy. Cortisol deficiency results in
98 adrenocorticotrophic hormone (ACTH) over-secretion due to loss of negative feedback along the
99 hypothalamic-pituitary-axis (1), consequently resulting in adrenal androgen excess (2). Accumulation
100 of steroids upstream of the enzymatic blockade is a hallmark of the disease. In 21OHD, steroid
101 precursor concentrations, especially 17-hydroxyporgesterone (17OHP), are substantially elevated
102 underlining its pivotal role in the diagnostic work-up. Serum 17OHP is also the traditional indicator of
103 adequate GC treatment in 21OHD. While in the general population, 17OHP is not a relevant source for
104 adrenal androgen secretion, its excessive formation plays an essential role in adrenal
105 hyperandrogenism in 21OHD (3-5).

106

107 Monitoring GC treatment to ensure optimal therapeutic effect and preventing hypo- or hyper-
108 androgenism is essential and a challenging task of clinical care in 21OHD. In addition to the
109 assessment of clinical parameters, the current guideline highlights the importance of regular and
110 consistently timed hormone measurements relative to medication schedules and time of the day, due
111 to their diurnal variance and dependency with regard to timing of GC replacement (6).

112 Disease monitoring is typically performed by morning blood tests before or after the intake of morning
113 medication. Earlier studies have confirmed a strong correlation between plasma and salivary steroids
114 in 21OHD supporting the idea of using this non-invasive monitoring strategy (7-10). Other approaches
115 to estimate overall GC and androgen exposure include measurement of urine steroid metabolites,
116 (serial) blood spots or steroid profiling in hair as potential long-term assessment of disease control
117 (11-14).

118

119 With regard to biomarkers, most clinicians measure serum 17OHP, androstenedione (A4) and
120 testosterone (T) concentrations and/or their metabolites in urine to assess disease control (15).
121 Additionally, 21-deoxycortisol (21DF) has been described as a promising marker for monitoring
122 21OHD (16,17).

123 Recently, it has also been found that the 11-oxygenated 19-carbon (11oxC19) androgens are a
124 clinically relevant androgenetic source and potential disease marker in 21OHD patients (18). The
125 11oxC19 androgens are derived from A4 which can be converted to 11 β -hydroxyandrostenedione
126 (11OHA4) by 11 β -hydroxylase (CYP11B1) and further to 11-ketoandrostenedione (11KA4) and
127 11-ketotestosterone (11KT) through the action of 11 β -hydroxysteroid dehydrogenase type 2 (11 β -
128 HSD2) (Figure 1) (19). In addition, 11oxC19 androgens also derive from 21DF (12). Hence,
129 concentrations of 11oxC19 steroids are significantly elevated in patients with classic 21OHD
130 compared to age-matched controls (18). The importance of 11KT and its derivate 11-
131 ketodihydrotestosterone (11KDHT) is highlighted by the fact that both act at the androgen receptor
132 with equal potency to their classic androgen counterparts, T and dihydrotestosterone (DHT)
133 respectively.

134 As 11oxC19 steroids are adrenal-specific androgens, they have been suggested as potentially novel
135 biomarkers for adrenal androgen excess in 21OHD (17).

136 A recent publication showed a reliable correlation between morning plasma and salivary
137 adrenal-specific androgens in 21OHD allowing a more comprehensive, non-invasive biomarker
138 profiling in 21OHD (20).

139 Given the pivotal role of ACTH-mediated acute steroidogenic response, including upregulation of
140 CYP11B1 and 11 β -HSD2 (21) and the distinctive diurnal rhythm of ACTH (22) and 17OHP (23), a
141 circadian secretion of 11oxC19 steroids seems obvious but has not been demonstrated so far.

142 We hypothesized that salivary 11OHA4 and 11KT-levels would follow a diurnal profile with higher
143 concentrations in the morning and lower concentrations in the evening in patients and controls.

144 The current study investigated diurnal variation of adrenal-specific androgens via salivary steroid day
145 profiles compared to controls as an effective non-invasive treatment monitoring tool.

146

147

148 **Subjects and Methods**

149 *Subjects*

150 Patients were recruited from the Endocrine Outpatient Clinic of the University Hospital Munich,
151 Germany. All patients provided written informed consent to participate in our registry and biobank for
152 adrenal insufficiency and differences of sex development (Bio AI/DSD, ethical approval no. 19-558).

153 All patients had genetically and/or clinically confirmed classic CAH due to 21OHD. The control group

154 was retrospectively selected from the control group of the German Cushing's Registry (NeoExNET,
155 ethical approval no. 152-10) after exclusion of Cushing's syndrome based on a comparable
156 anthropometric profile to the patient cohort (24). Exclusion criteria were defined as any condition or
157 medication known to affect steroid metabolism as well as having worked in shift work during the last
158 three months.

159 The study included 14 male and 20 female patients with CAH of whom 23 were suffering from salt
160 wasting (SW) and 11 of the simply virilizing (SV) form of CAH. The control subjects were BMI- and
161 age-matched (male, n = 15, female, n = 17).

162

163 Saliva samples were collected by carrying out saliva day profiles using saliva sampling via routinely
164 used salivettes (Sarstedt, Nümbrecht (DE)) at five timepoints throughout the day. For control patients
165 the following fixed timepoints were used: 08:00, 12:00, 16:00, 20:00 and 22:00 h. For CAH patients,
166 timepoints of saliva sampling were adjusted to the intake of GC medication, so that the five samples
167 were collected following the subsequent guidance: i) the first sample was collected upon awakening
168 before intake of the morning GC dose, ii) the second sample at approximately 10:00 h, iii) the third
169 sample at lunchtime, iv) the fourth sample in the afternoon at approximately 16:00 h and v) the last
170 sample was collected before bedtime at approximately 22:00 h. All participants had previously been
171 instructed on standardized use of salivettes.

172 One of the male and four of the female control patients were identified as outliers due to moderately
173 elevated baseline 17OHP measurements and excluded from further analysis (Table 1). These were
174 excluded from analysis and defined as outliers as lab parameters and original clinical parameters
175 suspected carriers of 21OHD or non-classic 21OHD. The final data set included 14 male patients and
176 14 male controls as well as 20 female patients and 13 BMI- and age-matched controls. Data sets with
177 three to four different timepoints of sample collection distributed throughout the whole day made up
178 20.0 to 42.9 % of the data sets analyzed. Incomplete data sets were mainly due to sporadic
179 interference in data analysis or insufficient sample volume. The numbers and percentage of data
180 points with values smaller than the lower limit of quantification (LLOQ) is listed per analyte. For values
181 lower than the LLOQ, values were equated to the respective LLOQ (Table 1).

182

183 *Steroid hormone analysis*

184 A validated LC-MS/MS assay was used for the simultaneous measurement of 17OHP, T, A4, 11OHA4
185 and 11KT (20,25). Standards and control solution containing a mixture of all analytes at the desired
186 concentrations were prepared by dissolving the steroid in ultra-pure methanol and further dilution in a
187 surrogate saliva matrix. The following analytes were used in the internal standard: [¹³C3]- (2,3,4)-17-
188 alpha-hydroxyprogesterone, [¹³C3]- (2,3,4)-androstene-3,17-dione, [¹³C3]- (2,3,4)-testosterone, D7-
189 2,2,4,6,6,16,16-4-Androsten-11β-ol-3,17-dione, D3-16,16,17-11-ketotestosterone. 250 μL of each
190 sample, as well as 20 μL of the internal standard mixture or the appropriate quality controls were
191 extracted by supported liquid extraction using methyl-tert-butyl-ether and then reconstituted with 40 %
192 (v/v) methanol. Chromatography was carried out on a Waters HSS T3 1.8 μm, 2.1 x 50 mm column,
193 with 2 mmol/L ammonium acetate, 0.1 % (v/v) formic acid in water as the aqueous mobile phase and
194 acetonitrile as the organic mobile phase. Quantification by mass spectrometry was then conducted
195 using a Waters XEVO TQ-XS system operated in positive ion mode. Standardized validation included
196 a mean recovery of 92.5 - 109.8 for all analytes at low, medium and high concentration, an intra-assay
197 coefficient of variation (26) of < 8.1 % with a bias between -6.6 and 4.2 and an inter-assay CV of <
198 11.4 % with a bias between -12.3 and 13.5 %. Lower limits of quantification (LLOQ) were defined as
199 12.5 pmol/L for 17OHP, 10 pmol/L for A4, 5 pmol/L for T, 45 pmol/L for 11OHA4 and 6 pmol/L for
200 11KT. The mean bias between direct sample analysis and overnight storage at 4 °C was 3.3 % for
201 17OHP, -2.6 % for A4, 1.2 % for T, 2.6 % for 11OHA4 and -1.8 % for 11KT. Carry-over at supra-
202 physiological concentrations of each analyte was 0.07 % for 17OHP, 0.05 % for A4, 0.03 % for T,
203 0.007 % for 11OHA4 and 0.03 % for 11KT (20,25).

204

205 *Statistical analysis*

206 For statistical analysis data was tested for normality using the Shapiro-Wilk test in conjunction with
207 graphical display by histogram and Q-Q plot. Column statistics were calculated using GraphPad Prism
208 (Mean, SEM, Quartiles). For longitudinal analysis hormone values were log-transformed before further
209 processing due to their non-normal distribution. For reasons of clarity only untransformed values are
210 reported. Due to the unbalanced design and missing datapoints, changes in salivary hormone values
211 during the day were examined by a linear mixed-effects model for repeated measures with time as
212 fixed and subject as random effect using an unstructured covariance structure (27). AUC was
213 calculated with baseline Y = 0, positive peak direction and ignoring peaks that are less than 10% of

214 the distance from minimum to maximum Y using GraphPad Prism. The percentage differences of
215 mean hormone levels (Δ_{mean}) were calculated by defining the fracture of evening hormone levels (time-
216 point 5) / morning hormone levels (time-point 1) and calculating the percentage change. Difference of
217 hormone levels between time-point 1 and 5 ($\Delta_{\text{hormone levels}}$) was identified by subtraction and presented
218 as mean (SEM) in pg/ml. Differences in AUC were examined using the Mann-Whitney-U test. For
219 correlation analysis Spearman's correlation coefficient was computed for non-parametric data. The
220 confidence interval was defined as 95% and a p-value of < 0.05 was considered statistically significant
221 $P \leq 0.05$ (≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***)). Statistical analysis and graphical presentation were
222 carried out using SPSS Statistics Software Version 26, GraphPad Prism 7.03 and Adobe Illustrator
223 2020.

224

225

226 **Results**

227 *Characteristics of study participants*

228 Median age was 29.5 years (IQR 23.8-37.3) in male (controls: 31.0 (25.0-42.0); $p = 0.805$) and 26.0
229 years (IQR 22.5-36.0) in female patients (controls: 26.0 (23.0-28.5; $p = 0.911$). Median BMI was 26.7
230 kg/m^2 in men (IQR 24.7-29.5) and 27.6 kg/m^2 in women with CAH (IQR (23.8-31.2), comparable to
231 controls (Table 3).

232 As depicted by Table 4, the majority of CAH patients received hydrocortisone (35.7 % of men and 55.0
233 % of women) or prednisolone (50.0 % of males and 40.0 % of females). Three patients (two men and
234 one woman) received dexamethasone. The mean equivalent dose applied varied between 22.5 mg
235 (13.10 mg/m^2) in women and 30 mg (14.74 mg/m^2) in men. All patients were on a circadian medication
236 scheme, none of them substituted in a reverse-circadian manner (Table 4).

237 According to biochemical and hormonal criteria, most patients were regarded as being well-controlled
238 in terms of androgen excess with the exception of two male and two female patients. In the female
239 CAH cohort, two patients were rather overtreated with suppressed androgen concentrations. Criteria
240 for assessment of therapeutic control were A4 and T AUC, as well as A4/T AUC ratio within the range
241 of the corresponding control group (6) (Table 2), while increased 17OHP AUC concentrations
242 compared to controls were regarded as target for patients with classic 21OHD.

243

244 *Diurnal rhythm of 17OHP and (adrenal-specific) androgens*

245 17OHP measurements showed a distinct diurnal rhythm with highest measurements in the early
246 morning and declining values throughout the day in both CAH patients and healthy controls, as
247 illustrated by Figure 2, Table 5 and 6 (male patients: $F_{1,11.841} = 2.660$; $p = 0.085$; $\Delta_{\text{mean}} = 75\%$; male
248 controls: $F_{1,13.630} = 16.670$; $p < 0.001$; $\Delta_{\text{mean}} = 42\%$; female patients: $F_{1,16.842} = 10.674$; $p < 0.001$; Δ_{mean}
249 $= 82\%$; female controls: $F_{1,13.040} = 9.115$; $p = 0.001$; $\Delta_{\text{mean}} = 51\%$). However, the morning peaks in
250 17OHP concentrations clearly varied between patients and controls with a more than ten-fold increase
251 in 17OHP in CAH patients. Correspondingly, for male patients with CAH, the AUC for 17OHP was
252 significantly larger than for respective controls ($AUC_{(\text{male patients})} = 3338.0 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $AUC_{(\text{male controls})} = 167.7$
253 $\frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $p = 0.001$; $AUC_{(\text{female patients})} = 1777.6 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $AUC_{(\text{female controls})} = 178.5 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $p = 0.088$).

254

255 A comparable diurnal rhythmicity could also be observed for A4, 11OHA4 and 11KT. Regarding A4,
256 the mean changes in a diurnal pattern were equally pronounced in CAH patients compared to
257 controls, while the inter-individual variance was higher in patients as expected (male patients: $F_{1,11.320}$
258 $= 2.298$, $p = 0.122$, $\Delta_{\text{mean}} = 42\%$; male controls: $F_{1,14.211} = 21.849$, $p < 0.001$, $\Delta_{\text{mean}} = 41\%$; female
259 patients: CAH women $F_{1,19.177} = 10.797$, $\Delta_{\text{mean}} = 30\%$; female controls: $F_{1,4.478} = 3.145$, $p = 0.133$,
260 $\Delta_{\text{mean}} = 30\%$).

261 Overall, A4 secretion was not significantly different from controls ($AUC_{(\text{male patients})} = 986.3 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$,
262 $AUC_{(\text{male controls})} = 654.1 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $p = 0.701$; $AUC_{(\text{female patients})} = 607.3 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $AUC_{(\text{female controls})} = 478.0$
263 $\frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $p = 0.250$).

264

265 11-OHA4 levels depicted a clear morning peak in both patients and control subgroups (male patients:
266 $F_{1,12.051} = 3.571$, $p = 0.038$, $\Delta_{\text{mean}} = 79\%$; male controls: $F_{1,13.409} = 55.993$, $p < 0.001$, $\Delta_{\text{mean}} = 81\%$;
267 female patients: $F_{1,15.920} = 12.912$, $p < 0.001$, $\Delta_{\text{mean}} = 33\%$; female controls: $F_{1, 21.085} = 25.971$, $p <$
268 0.001 , $\Delta_{\text{mean}} = 91\%$) with a nighttime increase only in female patients with CAH. Difference in the AUC
269 appeared larger in the male cohort compared to female subjects but failed to reach clinical
270 significance ($AUC_{(\text{male patients})} = 1470.0 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $AUC_{(\text{male controls})} = 1090.0 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $p = 0.794$; $AUC_{(\text{female}$
271 $\text{patients})} = 775.5 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $AUC_{(\text{female controls})} = 527.8 \frac{\text{pg} \times \text{t}(n)}{\text{ml}}$, $p = 0.294$).

272

273 Similarly, 11KT measurements also followed a diurnal rhythm with concentrations constantly declining
274 over the course of the day following an early morning peak (male patients: $F_{1,7.872} = 3.686$, $p = 0.056$;
275 $\Delta_{\text{mean}} = 64$ %; male controls: $F_{1,13.702} = 25.139$; $p < 0.001$; $\Delta_{\text{mean}} = 60$ %; female patients: $F_{1,15.942} =$
276 8.349 ; $p = 0.001$; $\Delta_{\text{mean}} = 49$ %; female controls: $F_{1,13.225} = 35.107$; $p < 0.001$; $\Delta_{\text{mean}} = 81$ %). An early
277 rise towards the night was only present in female patients with CAH, although there was no difference
278 in intake of evening GC dose between men and women. There was no significant difference in the
279 corresponding AUC between groups of either sex ($AUC_{(\text{male patients})} = 946.3 \frac{pg \times t(n)}{ml}$, $AUC_{(\text{male controls})}$
280 $= 752.1 \frac{pg \times t(n)}{ml}$, $p = 0.778$; $AUC_{(\text{female patients})} = 436.2 \frac{pg \times t(n)}{ml}$, $AUC_{(\text{female controls})} = 270.2 \frac{pg \times t(n)}{ml}$, $p = 0.863$).

281

282 The smallest degree of diurnal variation was seen in T measurements (male patients: $F_{1,12.619} = 5.935$,
283 $p = 0.006$, $\Delta_{\text{mean}} = 33$ %; male controls: $F_{1,12.888} = 9.763$, $p = 0.001$, $\Delta_{\text{mean}} = 25$ %; female patients:
284 $F_{1,12.100} = 5.832$, $p = 0.007$, $\Delta_{\text{mean}} = 34$ %; female controls: $F_{1, 8.585} = 4.596$, $p = 0.029$, $\Delta_{\text{mean}} = 14$ %).
285 Testosterone AUC was higher in males versus females, no statistical difference in AUC was observed
286 between male and female patients and controls ($AUC_{(\text{male patients})} = 557.0$, $AUC_{(\text{male controls})} = 500.0$, $p =$
287 0.667 ; $AUC_{(\text{female patients})} = 107.2$, $AUC_{(\text{female controls})} = 107.9$, $p = 0.472$).

288

289 *Correlation of (adrenal-specific) androgens with 17-OHP in healthy controls*

290 Control subjects showed significant correlations of 17OHP- and T-AUC ($r(p)_{\text{male}} = 0.622^*$; $r(p)_{\text{female}} =$
291 0.648^*) and male controls also a significant correlation of the AUC of 17OHP and A4 ($r(p)_{\text{male}} =$
292 0.855^{***} ; $r(p)_{\text{female}} = 0.429$) as depicted by Table 7 and 8. In contrast, 11KT ($r(p)_{\text{male}} = 0.345$; $r(p)_{\text{female}} =$
293 0.532) and 11OH4 ($r(p)_{\text{male}} = 0.429$; $r(p)_{\text{female}} = -0.192$) did not significantly correlate with 17OHP
294 concentrations in saliva.

295 In patients, the correlation between 17OHP measurements in saliva samples and T was weaker
296 compared to controls ($r(p)_{\text{male}} = 0.512$; $r(p)_{\text{female}} = 0.540^*$). 17OHP and A4 measurements in CAH
297 patients presented with a very strong correlation throughout the whole day ($r(p)_{\text{male}} = 0.706^{**}$; $r(p)_{\text{female}}$
298 $= 0.789^{***}$). Regarding the measured 11oxC19 androgens, a strong correlation could be observed
299 between 11KT and 17OHP in both male and female patients ($r(p)_{\text{male}} = 0.741^{**}$; $r(p)_{\text{female}} = 0.842^{***}$),
300 as well as a significant correlation for 11OHA4 and 17OHP measurements in female patients ($r(p)_{\text{male}}$
301 $= 0.385^{\text{n.s.}}$; $r(p)_{\text{female}} = 0.527^*$).

302 When correlating T and 11KT measurements in saliva samples of male patients with 21OHD, a
303 negative trend, but no significant correlation was observed ($r(p)_{\text{male}} = -0.033$).

305 **Discussion**

306 This is the first study to show that there is a clear circadian pattern for the investigated 11oxC19
307 androgens in the general population that is principally preserved or accentuated in patients with
308 21OHD. Our analysis therefore indicates that therapeutic monitoring of patients with 21OHD by
309 measurement of 11oxC19 steroids in saliva might be an efficient method, if using salivary profiles at
310 multiple timepoints throughout the day.

311

312 A diurnal profile with decreasing values from morning to evening has already been described for
313 17OHP, A4 and T (8,23,28). This physiological circadian rhythm in adrenal steroid hormone
314 production is mainly driven by the rhythmic release of ACTH, in response to corticotropin releasing
315 hormone (CRH) and vasopressin secretion from the paraventricular nucleus (PVN), which is under the
316 control of the master clock in the suprachiasmatic nucleus (SCN) (29). In addition, there is also a
317 peripheral adrenal clock that is tightly regulated by adrenal gland-specific time-controlled genes, such
318 as steroidogenic acute regulatory protein (StAR) (30). As StAR is involved in the rate limiting step of
319 steroid production, this results in a robust circadian rhythm of adrenal steroid synthesis (31). Here, we
320 have shown that this diurnal variation also applies to 11oxC19 steroid production following the pattern
321 of their precursor 17OHP (32).

322 Thus, 11oxC19 concentrations need to be interpreted with consideration of their diurnal variance and
323 sampling time. Furthermore, GC pharmacokinetics as well as circadian or reverse circadian
324 replacement regimen will impact on 11oxC19 steroid concentration. Due to low sample size we could
325 not analyze the effects of different modes of GC replacement in our study. It will be highly interesting
326 to explore the effects of immediate- versus modified-release hydrocortisone, intermediate and long-
327 term synthetic GC on salivary steroid day profiles in future studies.

328 It is yet unclear if 11oxC19 steroids have an advantage over established markers regarding treatment
329 outcomes. So far, there is no interventional study available exploring a potential difference in regard to
330 clinical outcomes by targeting 11oxC19 steroid levels in comparison to other markers such as A4 or
331 the A4/T-ratio (6,33). Given the close relationship of these steroids also raises the question if these
332 steroids can be independently targeted by treatment interventions (12,18). Conversely, there are
333 several studies suggesting that 11oxC19 steroids provide a major amount of additional information in
334 21OHD treatment monitoring and may be more suitable in adjusting GC treatment than currently used
335 biomarkers.

336 The current treatment goal has been defined by normalized androgens while elevated 17OHP has
337 been suggested as treatment target. It is generally accepted that while poorly controlled patients with
338 21OHD present with hugely elevated 17OHP levels, aiming for the reference range of healthy controls
339 results in overtreatment (6). It has been shown that while A4 and T are normalized in clinically well-
340 controlled patients with 21OHD, 17OHP concentrations are still elevated (34,35). In our study, 11OHA4
341 and 11KT secretion did not significantly differ from our control population throughout the day despite
342 significant inter-individual variations and excessively elevated 17OHP concentrations in patients
343 (12,18). This underlines that the utility of 17OHP as a treatment marker is restricted to detect
344 overtreatment.

345 Comparable A4, T and 11oxC19 androgens in patients and controls over the course of the day in our
346 study confirm that according to our initial assessment based on a single measurement of serum
347 steroids, overall disease control in our cohort was considered to be very good. This notion is further
348 supported by the fact that there was no significant difference in the AUC of A4 and T nor the AUC
349 A4/T ratio between patients and controls in our study (Table 5). Accordingly, it has been shown before
350 that 11oxC19 androgen measurements in patients with 21OHD show clear overlap with those of
351 healthy controls (20). Finally, a significant correlation of salivary 17OHP and 11oxC19 androgen
352 measurements was observed in patients but not in healthy controls (Table 7), indicating the limited
353 relevance of the 11oxC19 pathway in subjects with a functioning enzymatic pathway of
354 steroidogenesis (5).

355 A potential major advantage of 11oxC19 steroids over classic androgens in 21OHD might be that they
356 have proven adrenal origin and therefore might be better linked with clinical outcome markers (17).

357 Consequently, in patients with 21OHD, 11oxC19 concentrations were found to be associated with
358 increased adrenal volume, menstrual disturbances in women and the presence of testicular adrenal
359 rest tumor in males (17,18). A particular challenge in disease monitoring is that the currently used
360 classic biomarkers A4 and T are derived from both the adrenals and the gonads and their source
361 cannot be distinguished by laboratory methods. To help distinguish T from adrenal or testicular origin
362 in male patients with 21OHD it has been suggested to use the serum A4/T ratio (36). This is based on
363 the observation that A4 is elevated when androgens are predominantly of adrenal origin and result in
364 suppression of gonadotrophins and an elevated A4/T ratio. This is supported by the observation of
365 Turcu et al. who described a clear significant inverse correlation between T and 11KT measurements
366 in serum. It was hypothesized that due to the strong androgenic activity of 11KT, excessive secretion

367 results in suppression of the hypothalamic-pituitary-gonadal (HPG) axis in males with 21OHD (18).
368 This inverse correlation could not be confirmed in our study, albeit we observed a trend towards the
369 inverse correlation of T and 11KT. These discrepant results could be explained by the fact that, at the
370 timepoint of saliva sampling, most of the analyzed patients were under optimal hormonal control,
371 limiting the variance in T and 11KT concentrations during the course of the day. Analysis of 11oxC19
372 androgens would allow direct measurement of adrenal-derived androgens and salivary day profiling
373 will enable an integrated and coherent picture of adrenal steroid synthesis throughout the day.

374 In particular, salivary day profiling in 21OHD patients will help to overcome the challenge of precisely
375 timed blood sampling. Instead, it allows serial and more frequent day profiling in a non-invasive and
376 patient-friendly manner. In addition, it allows monitoring in a telemedicine setting providing access to
377 specialized tertiary care in this rare disease even in remote areas and in situations with travel
378 restrictions as the current pandemic situation.

379

380 Due to very good disease control in almost all patients of the study and hardly any cases with
381 undertreatment, limitations of this study were defined by a high percentage of measurements within
382 the LLOQ. Clinical use of ultra-performance convergence chromatography tandem mass spectrometry
383 (UPC²-MS/MS) for example could offer superior sensitivity resulting in even lower LOQs (37). In
384 addition, the timepoints of sample collection in patients and controls were not identical in this study,
385 leading to limited comparability of individual timepoints of data collection. However, our main goal in
386 this study was to show diurnal variations within and not between groups. Finally, given the sample
387 size, impact of different GC medications, immediate- versus modified-release GC, intermediate or
388 long-acting synthetic GC, could not be evaluated in this study. Fluctuations in salivary androgens in
389 relation and response to different GC replacement regimen therefore could not be analyzed in this
390 study and need to be explored in the future.

391

392 To conclude, this study is the first to describe the diurnal rhythm of 11oxC19 androgen concentrations
393 in salivary profiles in both healthy controls and patients with 21OHD. Our findings highlight that diurnal
394 fluctuations of 11oxC19 need to be considered for the assessment of biochemical disease control in
395 21OHD. Ultimately, comprehensive salivary day steroid profiling will improve patient management and
396 allow more frequent hormone measurements leading to more timely and accurate GC treatment
397 adjustments.

398

399 **Acknowledgments**

400 We thank all participants of this study.

401

402 **Author Contributions**

403 N.R. designed the study, H.N and M.K.A. contributed to the study concept. C.L., H.S. and I.D.
404 provided data. H.N. and M.K.A. conducted the statistical analysis. M.B. J.A. and J.H. performed the
405 laboratory analyses. H.N., M.K.A. and N.R. drafted the manuscript. All authors provided intellectual
406 input and read, revised and approved the final version of the manuscript.

407

408 **Data Availability**

409 The datasets generated during and/or analyzed during the current study are not publicly available but
410 are available from the corresponding author on reasonable request.

411

412 **References**

- 413 1. Ali SR, Bryce J, Haghpanahan H, Lewsey JD, Tan LE, Atapattu N, Birkebaek NH,
414 Blankenstein O, Neumann U, Balsamo A, Ortolano R, Bonfig W, Claahsen-van der
415 Grinten HL, Cools M, Costa EC, Darendeliler F, Poyrazoglu S, Elsedfy H, Finken MJJ,
416 Fluck CE, Gevers E, Korbonits M, Guaragna-Filho G, Guran T, Guven A, Hannema SE,
417 Higham C, Hughes IA, Tadokoro-Cuccaro R, Thankamony A, Iotova V, Krone NP, Krone
418 R, Lichiardopol C, Luczay A, Mendonca BB, Bachega T, Miranda MC, Milenkovic T,
419 Mohnike K, Nordenstrom A, Einaudi S, van der Kamp H, Vieites A, de Vries L, Ross
420 RJM, Ahmed SF. Real World Estimates Of Adrenal Insufficiency Related Adverse
421 Events In Children With Congenital Adrenal Hyperplasia. *J Clin Endocrinol Metab.*
422 2020.
- 423 2. Therrell BL. Newborn screening for congenital adrenal hyperplasia. *Endocrinol Metab*
424 *Clin North Am.* 2001;30(1):15-30.
- 425 3. Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA. Increased activation of
426 the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency:
427 evidence from urinary steroid hormone analysis. *J Clin Endocrinol Metab.*
428 2012;97(3):E367-375.
- 429 4. Pignatelli D, Pereira SS, Pasquali R. Androgens in Congenital Adrenal Hyperplasia.
430 *Front Horm Res.* 2019;53:65-76.
- 431 5. Turcu AF, Auchus RJ. Adrenal steroidogenesis and congenital adrenal hyperplasia.
432 *Endocrinol Metab Clin North Am.* 2015;44(2):275-296.
- 433 6. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg
434 HFL, Miller WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia
435 Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice
436 Guideline. *J Clin Endocrinol Metab.* 2018;103(11):4043-4088.

- 437 7. Shibayama Y, Higashi T, Shimada K, Kashimada K, Onishi T, Ono M, Miyai K, Mizutani
438 S. Liquid chromatography-tandem mass spectrometric method for determination of
439 salivary 17alpha-hydroxyprogesterone: a noninvasive tool for evaluating efficacy of
440 hormone replacement therapy in congenital adrenal hyperplasia. *J Chromatogr B
441 Analyt Technol Biomed Life Sci.* 2008;867(1):49-56.
- 442 8. Juniarto AZ, Goossens K, Setyawati BA, Drop SL, de Jong FH, Faradz SM. Correlation
443 between androstenedione and 17-hydroxyprogesterone levels in the saliva and
444 plasma of patients with congenital adrenal hyperplasia. *Singapore Med J.*
445 2011;52(11):810-813.
- 446 9. Bloem LM, Storbeck KH, Swart P, du Toit T, Schloms L, Swart AC. Advances in the
447 analytical methodologies: Profiling steroids in familiar pathways-challenging dogmas.
448 *J Steroid Biochem Mol Biol.* 2015;153:80-92.
- 449 10. de Groot MJ, Pijnenburg-Kleizen KJ, Thomas CM, Sweep FC, Stikkelbroeck NM, Otten
450 BJ, Claahsen-van der Grinten HL. Salivary morning androstenedione and 17alpha-OH
451 progesterone levels in childhood and puberty in patients with classic congenital
452 adrenal hyperplasia. *Clin Chem Lab Med.* 2015;53(3):461-468.
- 453 11. Storbeck K-H, Schiffer L, Baranowski ES, Chortis V, Prete A, Barnard L, Gilligan LC,
454 Taylor AE, Idkowiak J, Arlt W. Steroid metabolome analysis in disorders of adrenal
455 steroid biosynthesis and metabolism. *Endocrine Reviews.* 2019;40(6):1605-1625.
- 456 12. Kamrath C, Wettstaedt L, Boettcher C, Hartmann MF, Wudy SA. Androgen excess is
457 due to elevated 11-oxygenated androgens in treated children with congenital adrenal
458 hyperplasia. *J Steroid Biochem Mol Biol.* 2018;178:221-228.
- 459 13. Jha S, El-Maouche D, Marko J, Mallappa A, Veeraraghavan P, Merke DP.
460 Individualizing Management of Infertility in Classic Congenital Adrenal Hyperplasia
461 and Testicular Adrenal Rest Tumors. *J Endocr Soc.* 2019;3(12):2290-2294.
- 462 14. Auer MK, Krumbholz A, Bidlingmaier M, Thieme D, Reisch N. Steroid 17-
463 Hydroxyprogesterone in Hair Is a Potential Long-Term Biomarker of Androgen
464 Control in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
465 *Neuroendocrinology.* 2020;110(11-12):938-949.
- 466 15. Dauber A, Kellogg M, Majzoub JA. Monitoring of therapy in congenital adrenal
467 hyperplasia. *Clin Chem.* 2010;56(8):1245-1251.
- 468 16. Dahl SR, Nermoen I, Bronstad I, Husebye ES, Lovas K, Thorsby PM. Assay of steroids
469 by liquid chromatography-tandem mass spectrometry in monitoring 21-hydroxylase
470 deficiency. *Endocr Connect.* 2018;7(12):1542-1550.
- 471 17. Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, Tsodikov A, Auchus RJ,
472 Merke DP. 11-Oxygenated Androgens Are Biomarkers of Adrenal Volume and
473 Testicular Adrenal Rest Tumors in 21-Hydroxylase Deficiency. *J Clin Endocrinol Metab.*
474 2017;102(8):2701-2710.
- 475 18. Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, Merke DP,
476 Rainey WE, Auchus RJ. Adrenal-derived 11-oxygenated 19-carbon steroids are the
477 dominant androgens in classic 21-hydroxylase deficiency. *Eur J Endocrinol.*
478 2016;174(5):601-609.
- 479 19. Pretorius E, Arlt W, Storbeck KH. A new dawn for androgens: Novel lessons from 11-
480 oxygenated C19 steroids. *Mol Cell Endocrinol.* 2017;441:76-85.
- 481 20. Bacila I, Adaway J, Hawley J, Mahdi S, Krone R, Patel L, Alvi S, Randell T, Gevers E,
482 Dattani M, Cheetham T, Kyriakou A, Schiffer L, Ryan F, Crowne E, Davies JH, Ahmed
483 SF, Keevil B, Krone N. Measurement of Salivary Adrenal-Specific Androgens as

- 484 Biomarkers of Therapy Control in 21-Hydroxylase Deficiency. *J Clin Endocrinol Metab.*
485 2019;104(12):6417-6429.
- 486 21. Ruggiero C, Lalli E. Impact of ACTH Signaling on Transcriptional Regulation of
487 Steroidogenic Genes. *Front Endocrinol (Lausanne)*. 2016;7:24-24.
- 488 22. HPA Axis-Rhythms. *Comprehensive Physiology*:1273-1298.
- 489 23. Mezzullo M, Fazzini A, Gambineri A, Di Dalmazi G, Mazza R, Pelusi C, Vicennati V,
490 Pasquali R, Pagotto U, Fanelli F. Parallel diurnal fluctuation of testosterone,
491 androstenedione, dehydroepiandrosterone and 17OHprogesterone as assessed in
492 serum and saliva: validation of a novel liquid chromatography-tandem mass
493 spectrometry method for salivary steroid profiling. *Clin Chem Lab Med.*
494 2017;55(9):1315-1323.
- 495 24. Vogel F, Braun LT, Rubinstein G, Zopp S, Künzel H, Strasding F, Albani A, Riester A,
496 Schmidmaier R, Bidlingmaier M, Quinkler M, Deutschbein T, Beuschlein F, Reincke M.
497 Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission.
498 *The Journal of clinical endocrinology and metabolism*. 2020;105(12):dgaa625.
- 499 25. Schiffer L, Adaway JE, Arlt W, Keevil BG. A liquid chromatography-tandem mass
500 spectrometry assay for the profiling of classical and 11-oxygenated androgens in
501 saliva. *Ann Clin Biochem*. 2019;56(5):564-573.
- 502 26. Deterding K SC, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J,
503 Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla
504 A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP,
505 Wedemeyer H; HepNet Acute HCV IV Study Group. Ledipasvir plus sofosbuvir fixed-
506 dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1
507 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
508 *Lancet Infectious Diseases*. 2017;17(2):215-222.
- 509 27. Krueger C, Tian L. A Comparison of the General Linear Mixed Model and Repeated
510 Measures ANOVA Using a Dataset with Multiple Missing Data Points. *Biological*
511 *Research For Nursing*. 2004;6(2):151-157.
- 512 28. Debono M, Mallappa A, Gounden V, Nella AA, Harrison RF, Crutchfield CA, Backlund
513 PS, Soldin SJ, Ross RJ, Merke DP. Hormonal circadian rhythms in patients with
514 congenital adrenal hyperplasia: identifying optimal monitoring times and novel
515 disease biomarkers. *European journal of endocrinology*. 2015;173(6):727-737.
- 516 29. Oster H, Challet E, Ott V, Arvat E, de Kloet ER, Dijk DJ, Lightman S, Vgontzas A, Van
517 Cauter E. The Functional and Clinical Significance of the 24-Hour Rhythm of
518 Circulating Glucocorticoids. *Endocr Rev*. 2017;38(1):3-45.
- 519 30. Son GH, Chung S, Choe HK, Kim H-D, Baik S-M, Lee H, Lee H-W, Choi S, Sun W, Kim H,
520 Cho S, Lee KH, Kim K. Adrenal peripheral clock controls the autonomous circadian
521 rhythm of glucocorticoid by causing rhythmic steroid production. *Proc Natl Acad Sci*
522 *U S A*. 2008;105(52):20970-20975.
- 523 31. Chung S, Son GH, Kim K. Circadian rhythm of adrenal glucocorticoid: its regulation
524 and clinical implications. *Biochim Biophys Acta*. 2011;1812(5):581-591.
- 525 32. Turcu AF, Rege J, Auchus RJ, Rainey WE. 11-Oxygenated androgens in health and
526 disease. *Nat Rev Endocrinol*. 2020;16(5):284-296.
- 527 33. Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal
528 hyperplasia. *J Clin Endocrinol Metab*. 2013;98(7):2645-2655.
- 529 34. Lee PA, Urban MD, Gutai JP, Migeon CJ. Plasma Progesterone, 17-
530 Hydroxyprogesterone, Androstenedione and Testosterone in Prepubertal, Pubertal

- 531 and Adult Subjects with Congenital Virilizing Adrenal Hyperplasia as Indicators of
532 Adrenal Suppression. *Hormone Research in Paediatrics*. 1980;13(6):347-357.
- 533 35. Bode HH, Rivkees SA, Cowley DM, Pardy K, Johnson S. Home monitoring of 17
534 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood
535 samples. *The Journal of pediatrics*. 1999;134(2):185-189.
- 536 36. Auchus RJ. Management considerations for the adult with congenital adrenal
537 hyperplasia. *Mol Cell Endocrinol*. 2015;408:190-197.
- 538 37. Quanson JL, Stander MA, Pretorius E, Jenkinson C, Taylor AE, Storbeck KH. High-
539 throughput analysis of 19 endogenous androgenic steroids by ultra-performance
540 convergence chromatography tandem mass spectrometry. *J Chromatogr B Analyt
541 Technol Biomed Life Sci*. 2016;1031:131-138.
542

543

544 Legends for Figures and Tables

545

546 Figure legends

547

548 **Figure 1. Pathway of 11oxC19 androgen synthesis.** In patients with CAH due to 21OHD, 17OHP
549 accumulates, which translates to A4 overproduction. A4 is converted to 11OHA4 by CYP11B1 and
550 further to 11KT through the action of 11 β -HSD2. 11oxC19 androgens also derive from 21DF.

551

552 **Figure 2. Diurnal variation of 17OHP, A4, 11OHA4, T and 11KT levels in saliva of patients with**
553 **CAH and matched controls.** Saliva profiles consist of measurements at up to five different timepoints
554 throughout the day. Levels of 17OHP, A4, 11OHA4, T and 11KT were measured using LC-MS/MS.
555 Hormone levels of patients with CAH are illustrated in red, data of respective controls in black colour.
556 The mean of AUC of hormonal levels over the whole day are indicated per graph ($\frac{pg \times t(n)}{ml}$). Please note
557 that timepoints are not exactly the same in patients and controls.

558

559 Tables

560

Table 1. Characteristics of data set.

Variable	Men with CAH (n=14) (%)	Control men (n=15) (%)	Women with CAH (n=20) (%)	Control women (n=17) (%)
Number of data points	70	75	100	85

Incomplete data sets	6 (42.9)	3 (20.0)	6 (30.0)	7 (41.2)
Outliers (elevated 17OHP)	NA	1 (6.7)	NA	4 (23.5)
17OHP < LLOQ of 12.5	NA	8 (10.7)	20 (20.0)	14 (16.5)
11KT < LLOQ of 6	8 (11.4)	NA	24 (24.0)	10 (11.8)
11OHA4 < LLOQ of 40	11 (15.7)	6 (8.0)	27 (27.0)	12 (14.1)
T < LLOQ of 5	NA	NA	30 (30.0)	6 (7.1)
A4 < LLOQ of 10	NA	NA	17 (17.0)	1 (1.2)

Presentation of values as n (%). NA=not applicable.

561

562

Table 2. Assessment of therapy control of male and female patients with CAH.

Variable	Men with CAH (n=14) (%)	Women with CAH (n=20) (%)
AUC 17OHP	50.8 – 433.1 $\frac{pg \times t(n)}{ml}$	25.0 – 450.5 $\frac{pg \times t(n)}{ml}$
<i>Within reference range</i>	6 (42.9)	10 (50.0)
<i>Above reference range</i>	8 (57.1)	10 (50.0)
AUC A4	80.9 – 1518 $\frac{pg \times t(n)}{ml}$	57.7 – 1113.0 $\frac{pg \times t(n)}{ml}$
<i>Within reference range</i>	12 (85.7)	17 (85.0)
<i>Above reference range</i>	2 (14.3)	3 (15.0)
AUC T	112.9 – 1305.0 $\frac{pg \times t(n)}{ml}$	10.0 – 287.6 $\frac{pg \times t(n)}{ml}$
<i>Within reference range</i>	13 (92.9)	18 (90.0)
<i>Above reference range</i>	1 (7.1)	2 (10.0)
AUC A4/T ratio	0.72 – 2.76	1.83 – 12.45
<i>Within reference range</i>	12 (85.7)	18 (90.0)
<i>Out of reference range</i>	2 (14.3)	2 (10.0)

Presentation of values as n (%).

563

564

Table 3. Baseline characteristics of patients with CAH and controls.

Variable	Patients with CAH	Controls	p value
Men (n)	14	15	
<i>Age, years</i>	29.5 (23.8-37.3)	31.0 (25.0-42.0)	0.805
<i>BMI, kg/m²</i>	26.7 (24.7-29.5)	27.8 (23.0-31.1)	0.949
Women (n)	20	17	
<i>Age, years</i>	26.0 (22.5-36.0)	26.0 (23.0-28.5)	0.911
<i>BMI, kg/m²</i>	27.6 (23.8-31.2)	26.8 (23.0-31.7)	0.839

Presentation of values as median (IQR). Statistical differences calculated by Mann-Whitney test. P-value ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***).

565

566

Table 4. Medication of patients with CAH.

	Men with CAH	Women with CAH
Glucocorticoids		
<i>Hydrocortisone</i>	5 (35.7)	11 (55.0)
<i>Prednisolone</i>	7 (50.0)	8 (40.0)
<i>Dexamethasone</i>	2 (14.3)	1 (5.0)
<i>Equivalent dosage, mg</i>	30 (23.75 – 32.5)	22.5 (20.0 – 29.0)
<i>Equivalent dosage, mg/m²</i>	14.74 (12.30 – 18.04)	13.10 (11.60 – 14.22)
<i>Circadian administration regimen</i>	14 (100)	20 (100)
Fludrocortisone	9 (64.3)	14 (70.0)
<i>Dosage, mg</i>	0.1 (0.05-0.1375)	0.075 (0.05-1.0)

Presentation of values as median (IQR) or n (%).

567

568

Table 5. AUC of salivary hormone profiles of patients with CAH and controls.

AUC, $\frac{\text{pg} \times \text{t}(\text{n})}{\text{ml}}$	Patients with CAH	Controls	p-value
<i>Men</i>			
17OHP	3338.0 (1802.0)	167.7 (28.8)	0.001***
A4	986.3 (329.6)	654.1 (109.7)	0.701

	<i>11OHA4</i>	1470.0 (494.1)	1090.0 (230.1)	0.794
	<i>T</i>	557.0 (106.3)	500.0 (81.2)	0.667
	<i>11KT</i>	946.3 (356.8)	752.1 (122.8)	0.778
	<i>A4/T</i>	1.9 (0.6)	1.3 (0.1)	0.635
Women				
	<i>17OHP</i>	1777.6 (606.7)	178.5 (34.6)	0.088
	<i>A4</i>	607.3 (192.6)	478.0 (78.8)	0.250
	<i>11OHA4</i>	775.5 (134.0)	527.8 (105.8)	0.294
	<i>T</i>	107.2 (23.5)	107.9 (20.6)	0.472
	<i>11KT</i>	436.2 (124.8)	270.2 (55.4)	0.863
	<i>A4/T</i>	4.8 (0.6)	5.8 (1.0)	0.548

Presentation of values as mean (SEM). Statistical differences calculated by Mann-Whitney test. P-value ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***)

569

570

Table 6. Mean percentage difference of morning and evening salivary hormone levels in patients with CAH and controls.

		Δ_{mean}		$\Delta_{\text{hormone levels}}$	
		Patients	Controls	Patients	Controls
<i>Men</i>	<i>17OHP</i>	74.62	41.73**	924.6 (813.8)	31.7 (12.5)
	<i>A4</i>	41.70	40.77***	161.3 (112.2)	116.0 (29.0)
	<i>11OHA4</i>	78.99*	80.67***	768.3 (522.5)	673.6 (149.1)
	<i>T</i>	33.41*	25.05**	53.3 (14.47)	47.17 (13.21)
	<i>11KT</i>	63.81	59.70***	222.7 (112.5)	233.5 (31.0)
<i>Women</i>	<i>17OHP</i>	82.11***	50.64**	1364.0 (856.2)	59.2 (28.1)
	<i>A4</i>	30.30***	29.66	84.1 (26.7)	57.7 (22.3)
	<i>11OHA4</i>	32.71***	90.58***	120.6 (118.2)	380.4 (100.5)
	<i>T</i>	34.05*	14.29*	16.3 (4.7)	13.3 (5.1)

11KT 48.62** 81.16*** 134.1 (45.3) 120.6 (39.7)

Presentation of values as percentage difference of mean (Δ mean) morning (time-point 1) and evening (time-point 5) hormone levels (%). Presentation of difference of hormone levels between time-point 1 and 5 (Δ hormone levels) as mean (SEM) in pg/ml. Linear mixed-effects models with time as fixed and subject as random effects were calculated. P-value ≤ 0.01 (*), ≤ 0.001 (**), ≤ 0.0001 (***)).

571

572

Table 7. Correlation of AUC in male patients with CAH and controls.

		Males					
		17OHP	A4	11OHA4	T	11KT	
Patients with CAH	17OHP	-	0.706**	0.385	0.512	0.741**	
	A4	0.706**	-	0.304	0.701**	0.274	
	11OHA4	0.385	0.304	-	0.398	0.284	
	T	0.512	0.701**	0.398	-	-0.033	
	11KT	0.741**	0.314	0.284	-0.033	-	
Controls	17OHP	-	0.855***	0.429	0.622*	0.3450	
	A4	0.855***	-	0.429	0.802***	0.314	
	11OHA4	0.429	0.429	-	0.0989	0.780**	
	T	0.622*	0.802***	0.099	-	0.086	
	11KT	0.350	0.314	0.780**	0.086	-	

Spearman's correlation coefficient r. P-value ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***), ≤ 0.0001 (****).

573

574

Table 8. Correlation of AUC in female patients with CAH and controls.

		Females					
		17OHP	A4	11OHA4	T	11KT	
Patients with CAH	17OHP	-	0.789****	0.527*	0.540*	0.842****	
	A4	0.789****	-	0.364	0.834****	0.631**	
	11OHA4	0.523*	0.364	-	0.2091	0.645**	

Controls	T	0.540*	0.834****	0.209	-	0.349
	11KT	0.842****	0.631**	0.645**	0.349	-
		17OHP	A4	11OHA4	T	11KT
	17OHP	-	0.429	-0.192	0.648*	0.532
	A4	0.429	-	0.341	0.434	0.154
	11OHA4	-0.192	0.341	-	-0.170	0.070
	T	0.648**	0.434	-0.170	-	0.448
	11KT	0.532	0.154	0.070	0.448	-

Spearman's correlation coefficient r. P-value ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***), ≤ 0.0001 (****).

575

576



